簡(jiǎn)要描述:磷酸化乳腺癌抗雌激素耐藥蛋白1抗體免疫原:KLH conjugated synthesised phosphopeptide derived from human BCAR1 around the phosphorylation site of Tyr751
產(chǎn)品分類
Product Category相關(guān)文章
Related Articles詳細(xì)介紹
磷酸化乳腺癌抗雌激素耐藥蛋白1抗體
產(chǎn)品名稱 | 英文名稱 | 貨號(hào) |
磷酸化乳腺癌抗雌激素耐藥蛋白1抗體 | phospho-BCAR1 (Tyr751) | GOY-01K4407 |
商品屬性:
英文名稱: phospho-BCAR1 (Tyr751)
中文名:磷酸化乳腺癌抗雌激素耐藥蛋白1抗體
英文別名 :BCAR1
(phospho Y751); BCAR1(phospho Y751); p-BCAR1(p-Tyr751); Breast cancer anti
estro resistance 1 protein; BCAR 1; Bcar1; BCAR1_HUMAN; Breast cancer anti
estro resistance 1; Breast cancer anti-estro resistance protein 1; CAS; Cas
scaffolding protein family member 1; Crk associated substrate; Crk associated
substrate p130Cas; CRK-associated substrate; CRKAS; P130CAS.
交叉反應(yīng) :Human,
Mouse, Rat
標(biāo)記 :Unconjugated
抗體來源:Rabbit
抗體類型:Polyclonal
免疫原:KLH
conjugated synthesised phosphopeptide derived from human BCAR1 around the
phosphorylation site of Tyr751
蛋白細(xì)胞定位:細(xì)胞漿,細(xì)胞膜
純化方法:affinity
purified by Protein A
亞型:IgG
性狀:Liquid
濃度:1mg/ml
儲(chǔ)存液:0.01M TBS(pH7.4)
with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存條件:Shipped at
4℃. Store at -20 °C for one
year. Avoid repeated freeze/thaw cycles.
產(chǎn)品介紹:
p130 represents one of several known substrates
for v-Crk encoded p47. p130 Cas (for Crk-associated substrate) exhibits a
high level of tyrosine phosphorylation and is tightly associated with v-Crk,
suggesting a role in v-Crk-mediated cell signaling. The molecular cloning of
p130 Cas has shown it to represent a novel SH3 containing signaling molecule
with a cluster of multiple putative SH2-binding motifs for v-Crk. By
immunoprecipitation analysis, p130 Cas has been shown to be highly
phosphorylated at tyrosine residues subsequent to either v-Src p60 or
v-Crk-mediated transformation and to form stable complexes with both of these
transforming proteins. p130 Cas behaves as an extremely potent substrate for
protein tyrosine kinases and has been reported to relocate from the cytoplasm
to cell membrane upon tyrosine phosphorylation. One proposed model is that
the SH2 domain of v-Crk functions to activate c-Src kinase, which in turn
phosphorylates p130 Cas. |
多克隆抗體制備:
我公司合成抗原,保證陽(yáng)性血清和抗體ELISA效價(jià)達(dá)到1:32000,由蛋白抗原制備的多抗,保證WB檢測(cè)結(jié)果是陽(yáng)性。技術(shù)服務(wù)實(shí)行分步報(bào)價(jià),按節(jié)點(diǎn)收費(fèi),為客戶節(jié)約成本。
鼠單克隆抗體制備:
客戶可根據(jù)項(xiàng)目實(shí)際需求情況靈活選擇進(jìn)行,我公司將為您的項(xiàng)目提供專業(yè)的建議。在制備過程中,與客戶互動(dòng)驗(yàn)證,確保最終制備的抗體ELISA陽(yáng)性血清檢測(cè)達(dá)到合同要求的同時(shí),也能滿足客戶抗體最終應(yīng)用驗(yàn)證需求。技術(shù)服務(wù)實(shí)行分步報(bào)價(jià),按節(jié)點(diǎn)收費(fèi),為客戶節(jié)約成本。
重組抗體表達(dá)服務(wù):
重組抗體技術(shù)使制備人源化抗體和人源抗體成為可能,而這是其他常規(guī)的多克隆或單克隆抗體制備方法無法做到的。我公司已搭建好的抗體測(cè)序、重組抗體表達(dá)等先進(jìn)平臺(tái),能為客戶提供各種類型的重組抗體表達(dá)服務(wù),包含鼠源單克隆抗體構(gòu)建及表達(dá)、更換恒定區(qū)亞型的嵌合抗體表達(dá),抗體人源化改造及表達(dá)等服務(wù)。
單項(xiàng)免疫學(xué)及檢測(cè)服務(wù):
我公司也為客戶提供單項(xiàng)免疫學(xué)和檢測(cè)服務(wù),如動(dòng)物免疫、動(dòng)物飼養(yǎng)、抗體修飾服務(wù)(如FITC,HRP等的標(biāo)記)、以及ELISA,WB,IHC,DB等檢測(cè)服務(wù)。
抗體定制服務(wù):
已注冊(cè)商標(biāo),主要用于抗體藥物發(fā)現(xiàn)和開發(fā),是我公司針對(duì)有特定應(yīng)用要求和各種模型測(cè)試的客戶量身定制的專業(yè)服務(wù),主要面向工業(yè)客戶。
產(chǎn)品咨詢
歡迎您關(guān)注我們的微信了解更多信息
電話
微信掃一掃